Back to Search Start Over

Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea

Authors :
Eastwood, PR
Barnes, M
MacKay, SG
Wheatley, JR
Hillman, DR
Nguyen, X-L
Lewis, R
Campbell, MC
Petelle, B
Walsh, JH
Jones, AC
Palme, CE
Bizon, A
Meslier, N
Bertolus, C
Maddison, KJ
Laccourreye, L
Raux, G
Denoncin, K
Attali, V
Gagnadoux, F
Launois, SH
Eastwood, PR
Barnes, M
MacKay, SG
Wheatley, JR
Hillman, DR
Nguyen, X-L
Lewis, R
Campbell, MC
Petelle, B
Walsh, JH
Jones, AC
Palme, CE
Bizon, A
Meslier, N
Bertolus, C
Maddison, KJ
Laccourreye, L
Raux, G
Denoncin, K
Attali, V
Gagnadoux, F
Launois, SH
Publication Year :
2020

Abstract

BACKGROUND AND AIM: Hypoglossal nerve stimulation (HNS) decreases obstructive sleep apnoea (OSA) severity via genioglossus muscle activation and decreased upper airway collapsibility. This study assessed the safety and effectiveness at 6 months post-implantation of a novel device delivering bilateral HNS via a small implanted electrode activated by a unit worn externally, to treat OSA: the Genio™ system. METHODS: This prospective, open-label, non-randomised, single-arm treatment study was conducted at eight centres in three countries (Australia, France and the UK). Primary outcomes were incidence of device-related serious adverse events and change in the apnoea-hypopnoea index (AHI). The secondary outcome was the change in the 4% oxygen desaturation index (ODI). Additional outcomes included measures of sleepiness, quality of life, snoring and device use. This trial was registered with ClinicalTrials.gov, number NCT03048604. RESULTS: 22 out of 27 implanted participants (63% male, aged 55.9±12.0 years, body mass index (BMI) 27.4±3.0 kg·m-2) completed the protocol. At 6 months BMI was unchanged (p=0.85); AHI decreased from 23.7±12.2 to 12.9±10.1 events·h-1, a mean change of 10.8 events·h-1 (p<0.001); and ODI decreased from 19.1±11.2 to 9.8±6.9 events·h-1, a mean change of 9.3 events·h-1 (p<0.001). Daytime sleepiness (Epworth Sleepiness Scale; p=0.01) and sleep-related quality of life (Functional Outcomes of Sleep Questionnaire-10; p=0.02) both improved significantly. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35%. 91% of participants reported device use >5 days per week, and 77% reported use for >5 h per night. No device-related serious adverse events occurred during the 6-month post-implantation period. CONCLUSIONS: Bilateral HNS using the Genio™ system reduces OSA severity and improves quality of life without device-related complications. The results are comparable with prev

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1315731451
Document Type :
Electronic Resource